FDA — authorised 6 July 2022
- Application: NDA214487
- Marketing authorisation holder: CHEMOCENTRYX
- Indication: Labeling
- Status: approved
🇺🇸 Tavneos in United States
FDA authorised Tavneos on 6 July 2022
Marketing authorisation
Tavneos in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Rare Disease approved in United States
Frequently asked questions
Is Tavneos approved in United States?
Yes. FDA authorised it on 6 July 2022.
Who is the marketing authorisation holder for Tavneos in United States?
CHEMOCENTRYX holds the US marketing authorisation.